Home Companies Catalysts Deep Dives
Januvia sitagliptin APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaCVRM
Launch2006-10-16
US LOE2026-01-01
Peak Sales Est$3000M
Formulations[{"id":"januvia-po","doses":"25mg, 50mg, 100mg","route":"PO","setting":"PATIENT_SELF","frequency":"Q
Companies
MRK (ORIGINATOR)100%
Mechanism: DPP-4 inhibitor
Expert: Dipeptidyl peptidase-4 inhibitor that prevents degradation of endogenous GLP-1 and GIP, enhancing incretin-mediated glucose-dependent insulin secretion and glucagon suppression.
Everyday: Helps the body keep more of a natural hormone that lowers blood sugar after meals. A daily pill for type 2 diabetes.
Targets: ["DPP-4"]
Revenue History
PeriodRevenue ($M)
2023$2,892M
2024$2,268M
2025$2,100M
Q1 2024$670M
Q2 2024$629M
Q3 2024$482M
Q4 2024$487M
Q1 2025$550M
Q2 2025$520M
Q3 2025$510M
Q4 2025$520M
Programs (1)
IndicationStageKey StudyRegional Status
T2DAPPROVEDTECOS[{"stage":"APPROVED","region":"US","approval_date":"2006-10-16"}]
Notes
Declining due to GLP-1 competition and generic erosion. US LOE 2026.
Data from Supabase · Updated 2026-03-24